Navigation Links
Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting
Date:11/7/2008

administered erythropoiesis-stimulating agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in two clinical studies. Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.

Cancer:

-- ESAs shortened overall survival and/or increased the risk of tumor

progression or recurrence in some clinical studies in patients with

breast, non-small cell lung, head and neck, lymphoid, and cervical

cancers (see WARNINGS: Table 1).

-- To decrease these risks, as well as the risk of serious cardio- and

thrombovascular events, use the lowest dose needed to avoid red blood

cell transfusion.

-- Use ESAs only for treatment of anemia due to concomitant

myelosuppressive chemotherapy.

-- ESAs are not indicated for patients receiving myelosuppressive therapy

when the anticipated outcome is cure.

-- Discontinue following the completion of a chemotherapy course.

Perisurgery: PROCRIT (Epoetin alfa) increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.

Contraindications

-- PROCRIT is contraindicated in patients with uncontrolled hypertension or

with known hypersensitivity to albumin (human) or mammalian cell-derived

products.

Additional Important Safety Information

-- Patients with chronic renal failure experienced greater risks for death

and serious cardiovascular events (including myocardial infarction,

stroke, congestive heart failure, and hemodialysis vascular access

thrombosis) when administered ESAs to target higher versus lower

hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in two clinical

studies; these risks also increased in controlled cl
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
3. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
4. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
5. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
7. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
8. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/w3n5p6/drug_delivery_in ... new report "Drug Delivery in Central Nervous ... to their offering. The delivery of ... challenge in the treatment of neurological disorders. Drugs ... administered systematically (e.g., by intravenous injection) for targeted ...
(Date:6/2/2015)... , June 02, 2015 Research and Markets ( ... Processing Supplies and Equipment - Global Strategic Business Report" ... comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America ... provided for the period 2014 through 2020. Also, a seven-year ...
(Date:6/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/z9s8mp/laboratory ... "Laboratory Centrifuges - Global Strategic Business Report" ... and forecasts are provided for the period 2014 ... provided for these markets. Market data and analytics ... profiles are primarily based on public domain information ...
Breaking Medicine Technology:Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3Laboratory Centrifuges - Global Strategic Business Report 2014-2020: Developed Markets Slowdown, While Emerging Markets Surge 2
(Date:6/2/2015)... OR (PRWEB) June 02, 2015 ZOOM+, ... of ZOOM+ Performance Health Insurance, announced today the opening ... Clean White 57 - a three-in-one complete dental exam, ... Clean Jr. for kids. Like all ZOOM+ services, ZOOM+Smile ... , “Why shouldn’t the dentist office be as inviting ...
(Date:6/2/2015)... June 02, 2015 Olive ... opening of Surrey’s first fertility clinic. Surrey ... a diverse, young community, with one of ... , Until now patients from Surrey ... to come into Vancouver or Burnaby for ...
(Date:6/2/2015)... 2015 TU-Automotive Detroit is the biggest ... 150+ speakers include senior execs from GM, Chrysler, Mercedes, ... provide a crucial status update on the automotive technology ... just 24 hours to secure one of the remaining ... wait for tomorrow. There are 70 sessions looking across ...
(Date:6/2/2015)... June 02, 2015 Vancouver, BC ... iData Research ( http://www.idataresearch.com ), the bone graft ... bone matrices (DBM) over traditional allograft materials. Because ... and thus an increase in operation time, alternative ... market growth in these synthetic materials is partly ...
(Date:6/2/2015)... National Autism Resource has partnered with ... development agency, to launch its new website and strategic ... new website is designed to help parents and ... autism. The site will expand its product line for ... from easy to understand information and helpful links to ...
Breaking Medicine News(10 mins):Health News:ZOOM+ Opens Its First On-Demand ZOOM+Smile Studio and Reinvents the Dental Exam 2Health News:Olive Fertility Centre Opens First Fertility Clinic in Surrey BC 2Health News:The Connected Car’s Biggest Event is Here – TU-Automotive Detroit 2015 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 2Health News:Medtronic, DePuy Synthes Shift U.S. Bone Graft Substitute Market Towards Synthetic Demineralized Bone Matrices 3Health News:National Autism Resources Launches New Website, Delivering More Products and Services 2Health News:National Autism Resources Launches New Website, Delivering More Products and Services 3
... Action Preserves Beneficiary Access to High Quality Nursing ... JOPLIN, Mo., Aug. 7 Citing the substantial,benefit ... to Protect Senior Care (CPSC) today thanked,Senator Susan ... effort,in Congress to stop the Bush Administration from ...
... Beneficiary Access to High Quality Nursing Home Care;,Helps ... Aug. 7 Citing the substantial,benefit in protecting ... Senior Care (CPSC) today thanked,Senator Elizabeth Dole for ... to stop the Bush Administration from moving forward ...
... 7 The dietary health of children is in,urgent ... only forward-thinking,convenient solutions with a line of fresh, healthy ... Most health guidelines recommend,children consume about 400 calories a ... the Public Interest, a consumer group based in Washington,D.C., ...
... Management, Inc. has a proven track record in supporting ... work with the U.S. Army,s Phase I/II clinical testing ... in Silver Spring, MD. CRM is the premier ... to expand its infectious disease capabilities, it looked to ...
... the next five ... Millennium Research Group, WALTHAM, Mass., Aug. 7 ... Health Imaging Systems 2008 report,the market for adjunct breast ... dedicated breast MRI systems, and,breast-specific gamma imaging (BSGI) systems ...
... with Toledo Children,s Hospital and Good Samaritan Hospital, ... NORTH HOLLYWOOD, Calif., Aug. 7 IPC ... leading national hospitalist,physician group practice company, announced today ... Children,s Hospital in Toledo,Ohio and Good Samaritan Hospital ...
Cached Medicine News:Health News:Senator Susan Collins Praised for Leading Successful Effort to Derail $4.3 Million Maine Medicare Cuts 2Health News:Senator Elizabeth Dole Praised for Leading Successful Effort to Derail $22.1 Million North Carolina Medicare Cuts 2Health News:Kidfresh Offers a Solution to the Rise of Unhealthy Eating Among Children With Fresh and Nutritious Prepared Meals for Kids 2Health News:Clinical Research Management gets contract for trials of therapeutics against infectious diseases 2Health News:Clinical Research Management gets contract for trials of therapeutics against infectious diseases 3Health News:Adjunct Breast Imaging Market to Increase by Almost 28% per Year Through 2013 2Health News:IPC The Hospitalist Company Enters Ohio and Pennsylvania Markets 2
Adjustable speed vortex with inter-changeable heads , 110 V...
Inquire...
Adjustable speed vortex with inter-changeable heads, 110 V...
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
Medicine Products: